XML 49 R34.htm IDEA: XBRL DOCUMENT

Revenue from Contracts with Customers (Tables)

12 Months Ended

Dec. 31, 2024

During the years ended December 31, 2024, 2023 and 2022, the Company recorded product sales, net, as follows:


	Year Ended December 31,
(In thousands)	2024		2023		2022
VIVITROL	$	457,315	$	400,419	$	379,478
ARISTADA and ARISTADA INITIO		346,187		327,690		302,052
LYBALVI		280,032		191,889		96,022
Total product sales, net	$	1,083,534	$	919,998	$	777,552

Manufacturing and royalty revenues

Schedule of Disaggregation of Revenues

During the years ended December 31, 2024, 2023 and 2022, the Company recorded manufacturing and royalty revenues from its collaboration arrangements as follows:


	Year Ended December 31, 2024
(In thousands)	Manufacturing Revenue		Royalty Revenue		Total
Long-acting INVEGA products(1)	$	—	$	236,386	$	236,386
VUMERITY		39,292		94,755		134,047
RISPERDAL CONSTA		23,172		272		23,444
Other		56,962		23,256		80,218
	$	119,426	$	354,669	$	474,095


	Year Ended December 31, 2023
(In thousands)	Manufacturing Revenue		Royalty Revenue		Total
Long-acting INVEGA products(1)	$	—	$	486,101	$	486,101
VUMERITY		42,886		86,440		129,326
RISPERDAL CONSTA		36,123		1,153		37,276
Other		63,489		27,196		90,685
	$	142,498	$	600,890	$	743,388


	Year Ended December 31, 2022
(In thousands)	Manufacturing Revenue		Royalty Revenue		Total
Long-acting INVEGA products(1)	$	—	$	115,655	$	115,655
VUMERITY		32,493		83,003		115,496
RISPERDAL CONSTA		42,670		7,243		49,913
Other		37,211		13,708		50,919
	$	112,374	$	219,609	$	331,983

(1)

“long-acting INVEGA products”: INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate) and INVEGA HAFYERA/BYANNLI (paliperidone palmitate).